Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) is a clinical-stage biopharmaceutical company focused on inflammatory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). Its news flow centers on the development of its lead antibody candidate, rademikibart, and on corporate and regulatory milestones that shape the company’s trajectory.
Readers following CNTB news can expect regular updates on clinical progress, including recruitment status and topline data timing for the Phase 2 Seabreeze STAT asthma and Seabreeze STAT COPD studies, which evaluate rademikibart as an adjunct treatment for acute exacerbations. Company announcements also highlight new mechanism of action findings, post-hoc analyses of Phase 2b asthma data, and presentations at major medical meetings such as the European Respiratory Society Congress, the American Thoracic Society International Conference, and the European Academy of Allergy and Clinical Immunology Congress.
News items frequently cover regulatory and partnership developments, including the exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd. in Greater China and the submission and acceptance of a New Drug Application for rademikibart for atopic dermatitis by China’s National Medical Products Administration. Investors also see coverage of capital markets actions, such as the termination of the company’s American Depositary Receipt program and the direct listing of its ordinary shares on the Nasdaq Global Market under the symbol CNTB.
Additional CNTB news includes financial results, board appointments, and community initiatives, such as the collaboration with the Jovante Woods Foundation to expand asthma education programs. For investors, analysts, and healthcare observers, this news page provides a centralized view of Connect Biopharma’s clinical, regulatory, financial, and outreach activities related to rademikibart and its broader inflammatory disease focus.
Connect Biopharma (Nasdaq: CNTB) highlighted new mechanism‑of‑action data for rademikibart and outlined 2026 priorities, emphasizing clinical execution. Mechanistic studies show enhanced IL‑4R binding, greater internalization versus dupilumab, and stronger rescue of β‑agonist responsiveness in human airway models, supporting faster, larger FEV1 improvements observed previously. Ongoing Phase 1b IV study has shown preliminary faster FEV1 increases versus subcutaneous dosing with topline results expected in Q1 2026. Phase 2 Seabreeze STAT asthma and COPD trials are recruiting with topline data expected mid‑2026. Cash, cash equivalents and short‑term investments were $54.8M as of Sept 30, 2025, with runway into 2027 under current plans.
Connect Biopharma (Nasdaq: CNTB) announced that company management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 10:50 a.m. ET.
A live webcast will be available via the company's Investors website at investors.connectbiopharma.com, and an archived replay will be accessible on the site for approximately 90 days after the conference.
Connect Biopharma (Nasdaq: CNTB) reported third quarter 2025 results and a business update on Nov 12, 2025. Key developments include ongoing recruitment in Phase 2 Seabreeze STAT studies for acute asthma and COPD with topline data expected in 1H 2026, and presentation of positive Phase 2 asthma data at ERS 2025 showing larger lung-function gains in patients with baseline EOS ≥300 cells/μL and FeNO ≥25 ppb. Connect’s Greater China licensee, Simcere, had its NDA for rademikibart in atopic dermatitis accepted by China’s NMPA in July 2025; Connect is eligible for up to $110 million of remaining milestone payments plus tiered royalties. Corporate actions included terminating the ADR program and directly listing ordinary shares on Nasdaq under CNTB. Cash and short-term investments were $54.8M at Sept 30, 2025, expected to fund operations into 2027.
Connect Biopharma (NASDAQ:CNTB) presented promising data for rademikibart, their investigational anti-IL-4Rα antibody, at the European Respiratory Society Congress 2025. The Phase 2b trial results showed significant improvements in lung function and asthma control, particularly in patients with elevated type 2 inflammatory markers.
Key findings include a 507 mL improvement in prebronchodilator FEV1 at Week 24 in patients with high EOS and FeNO levels, and substantial reductions in asthma exacerbations (63% reduction in high EOS patients and 69% reduction in high FeNO patients). The company expects to report topline data from ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD in 1H 2026.
Connect Biopharma (Nasdaq: CNTB) announced two poster presentations at the upcoming European Respiratory Society (ERS) Congress 2025, scheduled for September 27 - October 1, 2025, in Amsterdam and virtually. Both presentations focus on Rademikibart, the company's treatment for asthma.
Dr. Raúl Collazo will present research on Rademikibart's effectiveness in moderate-to-severe asthma and its impact on FEV1 improvements in Type 2 Asthma. The presentations will take place on September 29th at 8:00 a.m. CET during Session #218 on Biologics for Asthma and Allergic Rhinitis. The presentations will later be available on Connect's website.
Connect Biopharma (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has completed the termination of its ADR program and transitioned to directly listing its ordinary shares on the Nasdaq Global Market. The company's ADRs were mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio on September 2, 2025.
Under the leadership of CEO Barry Quart, Connect Biopharma is positioning itself as a U.S.-centric company, focusing on developing treatments for asthma and COPD. The company is currently executing Phase 2 Seabreeze STAT studies for its drug candidate rademikibart, aiming to strengthen its relationship with U.S. investors and enhance shareholder value.
Connect Biopharma (NASDAQ: CNTB), a clinical-stage biopharmaceutical company specializing in inflammatory disease treatments, has announced its participation in two major investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference on September 3rd at 3:20 p.m. ET and the H.C. Wainwright Global Investment Conference on September 8th at 9:30 a.m. ET. Both presentations will be in a fireside chat format and available via webcast through Connect's investor relations website, with replays accessible for 90 days post-event.
Connect Biopharma (NASDAQ:CNTB) has partnered with former Cincinnati Bengals running back Ickey Woods and the Jovante Woods Foundation to expand a nationwide asthma education program. The initiative, launched on August 14, 2025, commemorates the death of Woods' 16-year-old son Jovante from an acute asthma attack in 2010.
The collaboration includes a video package featuring Jovante's story and will expand educational events across new U.S. markets during the 2025 NFL season. Connect Biopharma is currently conducting Phase 2 Seabreeze STAT studies for acute asthma exacerbations, with topline data expected in H1 2026.
According to CDC data, over 1 million people annually visit emergency departments for acute asthma exacerbations, with up to 30% requiring hospitalization. Approximately 50% experience worsening or new exacerbations within four weeks, and over 3,500 people die from asthma yearly in the U.S.
Connect Biopharma (NASDAQ:CNTB) reported Q2 2025 financial results and significant developments in its clinical programs. The company initiated Phase 2 Seabreeze STAT studies for rademikibart in asthma and COPD exacerbations, with topline data expected in H1 2026. Their partner Simcere submitted a new drug application to China's NMPA for rademikibart in atopic dermatitis treatment.
Financial highlights include cash position of $71.8 million as of June 30, 2025, expected to fund operations into 2027. The company reported a net loss of $12.9 million ($0.23 per share) for Q2 2025. Connect announced plans to terminate its ADR program and directly list ordinary shares on Nasdaq, aiming to improve institutional visibility and eliminate depositary fees.
Connect Biopharma (NASDAQ:CNTB) has appointed industry veteran Jim Schoeneck to its Board of Directors, expanding the board from six to seven members. Schoeneck brings over 40 years of experience in developing and commercializing breakthrough medicines.
Currently serving as Chairman of the Board for FibroGen, Inc. and Calidi Biotherapeutics, Schoeneck will contribute to advancing Connect's lead candidate rademikibart, which is being developed for acute exacerbations in asthma and COPD patients. The company expects clinical data from its Phase 2 Seabreeze STAT studies in the first half of 2026.
[ "Addition of experienced board member with 40+ years in biotech development and commercialization", "Strategic expertise in both organic and inorganic growth", "Relevant experience as Chairman of the National Board of Directors of the Asthma and Allergy Foundation of America" ]FAQ
What is the current stock price of Connect Biopharma Holdings (CNTB)?
What is the market cap of Connect Biopharma Holdings (CNTB)?
